Armata Pharmaceuticals公司2024年第四季度GAAP每股收益$(0.23)超过预期$(0.35),销售额$1.24百万低于预期$1.56百万

财报速递
21 Mar
Armata Pharmaceuticals (AMEX:ARMP) 公司报告季度每股亏损$(0.23),比分析师一致预期的$(0.35)高出34.29%。与去年同期每股亏损$(0.55)相比,提升了58.18%。公司报告季度销售额为$1.24百万,低于分析师一致预期的$1.56百万,减少20.83%。与去年同期销售额$1.53百万相比,下降了19.18%。

以上内容来自Benzinga Earnings专栏,原文如下:

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.35) by 34.29 percent. This is a 58.18 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $1.24 million which missed the analyst consensus estimate of $1.56 million by 20.83 percent. This is a 19.18 percent decrease over sales of $1.53 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10